西藏药业（600211）(600211.SH)发布公告，公司拟以1.7亿元至2亿元回购股份，回购价格不超过55元/ 股，将用于实施股权激励或员工持股计划。 ...

人民财讯12月18日电，西藏药业（600211）12月18日公告，公司拟以1.7亿元—2亿元通过集中竞价交易 方式回购股份，用于实施股权激励或员工持股计划，回购股份价格不超过55元/股。 ...

智通财经APP讯，西藏药业(600211.SH)发布公告，公司拟以1.7亿元至2亿元回购股份，回购价格不超过 55元/股，将用于实施股权激励或员工持股计划。 ...

证券日报网12月9日讯西藏药业在11月1日至11月30日回答调研者提问时表示，新活素医保最终结果请关 注医保局通知及公司后续公告。 （文章来源：证券日报） ...

（编辑 王雪儿） 证券日报网12月9日讯 西藏药业在11月1日至11月30日回答调研者提问时表示，医药行业属于典型的政 策性驱动行业，且产品销售会受到宏观环境、行业政策、市场环境变化多种因素影响。目前新活素已覆 盖医疗机构近7000家，公司将进一步加强与商业公司合作，利用商业公司资源去开发新医院，扩大新活 素覆盖机构数，持续做好学术推广工作；此外，公司已启动新活素循证医学探索性研究，进一步拓展销 售。通过一系列措施保持新活素销量稳健。 ...

Core Viewpoint - Xizang Pharmaceutical emphasizes the significance of in vivo gene editing technology as a major breakthrough in life sciences, offering revolutionary treatment options beyond hereditary diseases, including metabolic, infectious diseases, and cancer [1] Group 1: In Vivo Gene Editing - In vivo gene editing allows for precise modifications to the genome, enabling knockouts, knockdowns, or insertions [1] - The technology presents substantial advantages in terms of efficacy, market potential, and cost-effectiveness, with the possibility of one-time cures [1] Group 2: Technological Platforms - Ruizheng Gene has established a comprehensive technology system with three major platforms: nucleic acid platform, gene editing platform, and delivery technology platform [1] - This end-to-end technology framework supports the full chain of gene editing processes [1]

Core Viewpoint - The announcement by Tibet Pharmaceutical indicates that its subsidiary, Chengdu Nodi Kang Biopharmaceutical Co., Ltd., has its product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), included in the National Medical Insurance Directory for 2025 and adjusted to the regular directory [1] Group 1 - The product will continue to be covered by the national medical insurance, which is a significant advantage for the company [1] - The adjustment to the regular directory may enhance the product's market accessibility and potential sales [1]

Group 1 - The core product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), has been included in the National Medical Insurance Directory and adjusted to the regular category, effective January 1, 2026 [1][4] - Xinhuasuan is a first-class new biological product developed by the company, used for treating acute heart failure, improving symptoms and quality of life for patients, while also reducing hospitalization costs and duration [1][2] - The product's production and sales figures indicate strong performance, with 7.35 million units produced and 7.01 million units sold in 2024, generating revenue of 2.433 billion yuan, accounting for 86.89% of the company's main business income [3] Group 2 - The adjustment to the regular category is expected to have a positive impact on the company's future product sales and long-term development, although the specific impact on operating performance cannot yet be estimated [4]

Core Viewpoint - Tibet Pharmaceutical (600211) has seen a positive market response following the announcement that its subsidiary's product, Xinhuasuan, has been included in the National Medical Insurance Drug List for 2025, which is expected to enhance future sales and operational development [1][2]. Group 1: Company Performance - As of December 8, 2025, Tibet Pharmaceutical's stock closed at 41.97 CNY, up 0.65% from the previous trading day, with a total market capitalization of 13.528 billion CNY [1]. - The stock opened at 41.78 CNY, reached a high of 42.19 CNY, and recorded a low of 41.78 CNY, with a trading volume of 96.8223 million CNY and a turnover rate of 0.71% [1]. Group 2: Product and Market Impact - The product Xinhuasuan, a recombinant human brain natriuretic peptide injection, is primarily used for the short-term treatment of acute decompensated heart failure and is limited to use in secondary and higher medical institutions [1]. - In 2024, Xinhuasuan is projected to generate sales revenue of 2.433 billion CNY, accounting for 86.89% of the company's main business revenue; in the first half of 2025, it is expected to generate 1.456 billion CNY, representing 88.36% of the revenue [1]. - The inclusion of Xinhuasuan in the regular drug list is anticipated to have a positive impact on the company's future sales and operational growth [1].

Core Viewpoint - The announcement regarding the inclusion of the drug Xinhuasuan in the national medical insurance drug list indicates a significant shift for the company, as it transitions from a negotiable agreement drug to a stable inclusion in the regular catalog, enhancing long-term revenue predictability [1][2]. Group 1: Product and Market Impact - Xinhuasuan, developed by the company's subsidiary Chengdu Nuodikan Biopharmaceutical Co., Ltd., is a new biological product for treating acute heart failure, which improves patient symptoms and reduces hospitalization costs [1]. - The sales volume for Xinhuasuan is projected to reach 7.0083 million units in 2024, generating revenue of 2.433 billion yuan, with 4.1672 million units and 1.456 billion yuan expected in the first half of 2025 [2]. - The drug's penetration in the large heart failure market remains low, indicating substantial growth potential following its transition to the regular catalog, which will stabilize pricing and support long-term performance growth [2]. Group 2: Additional Developments - The company’s associate, Chentai Pharmaceutical, has also seen its drug Zorifertinib included in the medical insurance catalog, with a negotiation agreement effective from January 1, 2026, to December 31, 2027 [2]. - Zorifertinib is recognized as the first drug targeting advanced non-small cell lung cancer with central nervous system metastasis, which is expected to accelerate its commercial value realization after being included in the insurance catalog [2].